FOR IMMEDIATE RELEASE

ASX Waiver for the General Meeting That was held on Monday 28 February 2011

Sydney, Australia 3rd March 2011 - NuSep (ASX: NSP) wishes to advise the market that it applied for a waiver from ASX Listing Rule 7.3.8 and 14.11 to allow the shareholders who participated in the November 2010 share placement and the December 2010 Share Purchase Plan to vote on the issue of the share options at the General Meeting that was held on 28 February 2011.

The ASX has advised that it has granted a waiver to allow only those shareholders who participated in the December 2010 Share Purchase Plan to vote at the General meeting to be held on Monday 28 February 2011.

This General Meeting was held on Monday 28 February 2011 and the motion was passed by a show of hands on the day. The Board did note before the vote at the meeting that it would disregard any votes cast by people who had taken part in the November 2010 placement. The 12,883,447 proxy votes cast in favour of this motion was prepared on this basis.

****ENDS****

For more information please contact:

Contact:
Prakash Patel
Company Secretary
+61 2 8197 3377
prakash.patel@nusep.com

Released through: Fergus Ross, Six Degrees Investor Communication: +61 420 980 448

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative ηUView Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2008 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.
- **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm's process is based on the **Pr**eparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm's process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.